GENE THERAPY VECTORS: VIRAL AND NON-VIRAL SYSTEMS

“𝔾𝕖𝕟𝕖 𝕥𝕙𝕖𝕣𝕒𝕡𝕪 𝕚𝕤 𝕟𝕠𝕥 𝕪𝕖𝕥 𝕡𝕠𝕤𝕤𝕚𝕓𝕝𝕖, 𝕓𝕦𝕥 𝕞𝕒𝕪 𝕓𝕖𝕔𝕠𝕞𝕖 𝕗𝕖𝕒𝕤𝕚𝕓𝕝𝕖 𝕤𝕠𝕠𝕟, 𝕡𝕒𝕣𝕥𝕚𝕔𝕦𝕝𝕒𝕣𝕝𝕪 𝕗𝕠𝕣 𝕨𝕖𝕝𝕝 𝕦𝕟𝕕𝕖𝕣𝕤𝕥𝕠𝕠𝕕 𝕘𝕖𝕟𝕖 𝕕𝕖𝕗𝕖𝕔𝕥𝕤…” - Dr. Robert Williamson

🧬 Gene therapy has been a transformative approach to treating genetic disorders by directly modifying gene expression in patient cells. Central to its success is the delivery method, gene therapy vectors; classified broadly into viral & non-viral systems. Each comes with distinct advantages & limitations, making vector choice critical for therapeutic efficacy & safety.
          🔹 Viral vectors are engineered from viruses with pathogenic elements removed or altered. Common examples include retroviruses, adenoviruses, adeno-associated viruses (AAV), & lentiviruses. Their main strength lies in their natural ability to infect host cells efficiently, enabling high transduction rates, & in some cases, stable gene integration for long-term expression. This makes them highly effective for applications like somatic gene therapy, including treatments for β-thalassemia & sickle cell disease. However, they present challenges: immune reactions may limit therapeutic effect & cause toxicity, integration can risk insertional mutagenesis, & large-scale manufacturing is complex & costly.
          🔹 Non-viral vectors rely on physical & chemical delivery methods, such as liposomes, nanoparticles, electroporation, & microinjection. They are generally safer, eliciting minimal immune responses, & allow flexible, large-capacity DNA packaging. They are also easier & more economical to produce. However, their lower transfection efficiency, difficulty in nuclear delivery, & predominantly transient gene expression limit their use in conditions requiring long-lasting effects. Still, they are valuable for DNA vaccines, temporary gene editing via #CRISPR/Cas9, & cancer immunotherapy.
           🔹 The choice between viral & non-viral systems depends on therapeutic goals. Viral vectors excel when sustained expression is essential, while non-viral systems suit short-term applications where safety & rapid production are priorities.
          ➡️ Advances are reshaping both approaches, from “stealth” viral capsids & split/self-complementary AAVs to ligand-targeted nanoparticles with hybrid systems emerging to merge viral efficiency with non-viral safety.

⚠ In an Oystershell, both viral & non-viral vectors are vital to the progress of gene therapy. Each offers unique strengths suited to specific applications. With ongoing innovation, hybrid & next-generation delivery platforms may expand treatment possibilities, improving patient outcomes across a spectrum of genetic disorders.

Abubakar Abubakar ✍🏻

• Ginn SL, et al. J Gene Med 2018;20(5):e3015.

• Ramamoorth M, et al. J Clin Diagn Res. 2015;9(1):GE01–GE06.

• Wang D, et al. Nat Rev Drug Discov. 2019;18(5):358–378.

#GeneTherapy #Vectors #Virus🔬💉